Recent Events & Catalysts
Dianthus Therapeutics, Inc. (DNTH) — real, dated facts. Not a claim about what caused any single day's price move.
Committee Signals
Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.
No committee signals recorded yet.
News
Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128
Benzinga · 5d ago
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158
Benzinga · 5d ago
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122
Benzinga · 6d ago
Dianthus Therapeutics Q2 EPS $(0.90) Misses $(0.88) Estimate, Sales $761.000K Beat $258.583K Estimate
Benzinga · 7d ago
Dianthus Therapeutics Announces New Pipeline Candidate, DNTH312 for Autoimmune Disorders; The Company Expects DNTH312 to be Phase 1 Ready By End Of 2027
Benzinga · 7d ago
Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134
Benzinga · 8d ago
SEC Filings (90 days)
Results of operations (earnings release), Financial statements and exhibits
Filed 2026-08-04 · 8d ago · Material
Other events, Financial statements and exhibits
Filed 2026-06-12 · 61d ago
Submission of matters to a vote of security holders
Filed 2026-05-22 · 82d ago
Earnings
No recent earnings data available.
Latest Analyst Action
No recent analyst actions available.